Omitting surgical axillary staging for patients with breast‐conserving therapy

CANCERadditional option for patients who would be good candidates for the combination regimen.She cautions, however, about keeping in mind that some patients may not be ideal candidates for the combination, and in that setting, single-agent pembrolizumab would be sufficient and still is effective.She says that the results will "likely mean a change in clinical guidelines for the combination and making it an option for patients, if appropriate."